Chronic myeloproliferative neoplasms in the elderly

Eur J Intern Med. 2018 Dec:58:33-42. doi: 10.1016/j.ejim.2018.05.005. Epub 2018 May 22.

Abstract

This review focuses on the management of elderly patients with chronic myeloid leukemia and chronic myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis. Median age in these neoplasms is within the 6th decades of age. All new therapies can be done at any age without absolute contraindication. However, the selection of the precise therapy for the single patient is mandatory. For these reasons, an accurate definition of diagnosis and prognostication is necessary. Precision in disease definition and prognostication is definitively helpful for personalizing therapeutic approach.

Keywords: Chronic myeloid leukemia; Myelofibrosis; Polycythemia; Thrombocythemia.

Publication types

  • Review

MeSH terms

  • Aged
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Janus Kinase 2 / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Mutation
  • Polycythemia Vera / genetics
  • Polycythemia Vera / therapy*
  • Primary Myelofibrosis / genetics
  • Primary Myelofibrosis / therapy*
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Stem Cell Transplantation
  • Thrombocythemia, Essential / genetics
  • Thrombocythemia, Essential / therapy*

Substances

  • Janus Kinase 2